Chapter 19. ACUTE AND SUBACUTE, AND RIEDEL’S THYROIDITIS

One cohort (n=132) was included regardless of PD-L1 tumour status. Efficacy is reported for 174 patients with recurrent and/or metastatic HNSCC that progressed on or after treatment with platinum-containing chemotherapy. Patients with active autoimmune disease or a medical condition that required immunosuppression were ineligible. ................
................